Position value approximately $129 million, Cypherpunk Technologies reports Q2 net profit of $39.39 million

Odaily News: ZEC treasury company Cypherpunk Technologies (Nasdaq: CYPH) has released its Q2 2026 financial report, posting a net profit of $39.39 million, or $0.18 diluted earnings per share; in the same period last year, the company reported a net loss of $16.64 million and an operating loss of $4.69 million. R&D expenses stood at $0.2 million, down from $10.54 million in the same period last year, primarily due to the completion of clinical trials; general and administrative expenses reached $4.49 million, up $2.75 million year-over-year, mainly driven by increased stock-based compensation. As of June 30, the company's cash balance was $7.6 million.



During Q2, the ZEC price rose from $243.35 to $400.09, generating approximately $46 million in non-cash unrealized gains for the company. As of August 11, 2026, the company held a cumulative total of 323,400 ZEC, with an average cost basis of approximately $341.83, representing about 1.92% of ZEC's total circulating supply.



On the business development front, the company has appointed Dev Ojha, founder of Valar Group, as an advisor. Valar Group focuses on Zcash network development and research, and has led the development of the high-performance full node software Zakura and the Ironwood shielded pool. The company's subsidiary, Leap Therapeutics, has reached an agreement with the U.S. FDA on the Phase III clinical trial design for sirexatamab (anti-DKK1 monoclonal antibody), and received FDA Fast Track designation in May 2026 for the treatment of patients with second-line metastatic colorectal cancer with high DKK1 expression. The company has also initiated a strategic process to evaluate pathways for advancing sirexatamab development through independent financing or collaboration with partners.